Axiscades swings to ₹14.8 Cr Q1FY27 loss on one-off Akkodis costs; revenue up 42% YoY
PAT -170.79% YoY · revenue +42.22% · margins compressing
₹346.6 Cr
+42.22% YoY
₹-14.76 Cr
-170.79% YoY
-4.21%
-12.4pp YoY
₹-3.49
Axiscades reported a consolidated net loss of ₹14.76 Cr for the quarter ended June 30, 2026 (Q1 FY27) — a sharp reversal from the ₹20.86 Cr profit a year ago and the marginal ₹0.41 Cr profit in Q4 FY26 — even as total revenue (continuing + discontinued operations) grew 42.2% YoY to ₹346.60 Cr (+27.0% QoQ from ₹273.01 Cr). The swing was driven almost entirely by a ₹21.81 Cr one-off advisory/professional-fee charge tied to the ongoing divestment of two legacy service lines to Akkodis, booked within discontinued operations; adjusted for this item, PAT would have been a positive ~₹7.05 Cr, still down ~66.2% YoY on an adjusted basis. Consolidated basic EPS was -₹3.49 versus +₹4.88 a year ago. Standalone results mirrored the pattern — a ₹13.87 Cr net loss (EPS -₹3.26) against a ₹6.56 Cr profit a year ago.
Q1 FY-2027 vs prior quarters
Consolidated NPM swung to roughly -4.3% from +8.2% a year ago. The pressure sits mainly in continuing operations (the post-carve-out core of Defence plus retained Technology Services), where revenue nearly doubled YoY to ₹183.35 Cr (+94.2%) — Defence alone grew 111.5% to ₹124.99 Cr, comfortably ahead of management's guided >40% core-domain growth — but costs grew faster: employee expense +30.2% to ₹48.30 Cr, finance costs +36.8% to ₹8.87 Cr, and depreciation +82.9% to ₹8.75 Cr, as the company ramps capacity for the new large-scale Defence facilities (radars, missiles) flagged in its guidance. That capex shows up directly in the quarter's corporate actions: a ₹39.4 Cr land acquisition completed July 24, 2026. Discontinued operations (the businesses being sold) also cooled — pre-exceptional profit fell 34.1% YoY to ₹16.39 Cr even as their revenue rose 9.4% to ₹163.25 Cr — margin compression that, combined with the Akkodis deal costs, did most of the damage to the bottom line.
The stock went into the print at ₹1,535, down 4.7% over the past month of trading.
For context: PAT has now risen for 2 consecutive quarters; revenue is at a 6-quarter high.
Management confidently reaffirms its guidance for 40-50% annual EPS growth for both FY26 and FY27, driven by over 40% growth in its core domains. The company is accelerating its strategic shift from services to higher-margin products and solutions, aiming to flip the revenue mix from 39% products to over 60% by FY27. T
— This quarter: missed
We have no management press release for this specific result on file, so this read is based on the filing alone. Management's prior guidance (Q3 FY26 concall) called for 40-50% annual EPS growth in both FY26 and FY27 and EBITDA margin expansion from ~17% (FY26) to 20% (FY27), underpinned by a shift toward higher-margin defence products. Q1's swing to a loss — or even the adjusted ~66% YoY PAT decline — is a weak opening quarter against that bar, though it is one of four and dominated by a one-off deal cost; the revenue-mix and core-growth legs of the guidance, by contrast, are tracking well. No specific street/consensus estimate for this quarter turned up in a web search; the only external figure on record is management's own FY27 consolidated revenue trajectory of ~₹1,377 Cr (reiterated after FY26 results), against which this quarter's ₹346.60 Cr run-rate is broadly on pace. The quarter's governance actions — Ashmita Sethi's appointment as independent director (Aug 11) and the board/committee reconstitution — are housekeeping tied to the upcoming Akkodis transaction rather than operational drivers.
W1
Akkodis divestment closing (targeted Q2 FY27) — watch for the extraordinary gain booking (externally reported at ~₹175 Cr) and the resulting post-divestment continuing-ops-only revenue base.
W2
FY27 guidance of 40-50% annual EPS growth — Q1 adjusted PAT down ~66.2% YoY makes this a stretch target; watch Q2-Q4 trajectory for a recovery.
W3
EBITDA margin path toward management's 20% FY27 target from ~17% in FY26 — Q1 continuing-ops margins compressed on rising employee/finance/depreciation costs from new Defence capacity.
Restructuring Loss Masks Weak Operational Core; FY27 Guidance Binary on M&A
A reported loss of ₹14.8 crore inflated by ₹34.91 crore in one-time costs; normalized PAT is roughly ₹20.2 crore. But the real tension: FY27 guidance is pro-forma, contingent on 4 acquisitions, and the ₹4,557 crore order book is multi-year visibility, not imminent revenue.
-₹14.8 Cr
Includes ₹34.91 Cr one-time costs: transaction, provisions, hedge unwinding
~₹20.2 Cr
Adjusted for restructuring; reflects operational baseline
₹8.7 Cr
4.7% margin; normalized claimed ~11.8% (math unclear)
The restructuring bill
Q1 profit was flattened by three layers of one-time costs totaling ₹34.91 crore: ₹21.81 crore in divestment transaction costs (the Akkodis deal), ₹13.1 crore in receivable provisioning largely on an aged defense contract, and ₹3.5 crore in hedge unwinding. These are real costs tied to the restructuring, but they obscure true operational performance. Strip them out and the company was barely profitable—normalized PAT of roughly ₹20.2 crore on ₹183 crore revenue, or about 11% net margin. That's not the picture of a restructuring success story.
What management claimed—and what holds up
Normalized EBITDA ₹41 Cr at 11.8% margin, up from 20.5% YoY
Math doesn't align: 41/183 = 22.4%, not 11.8%. Likely blends continuing + discontinued ops or uses different revenue base. Cannot verify from stated numbers.
Overstated
Continuing ops revenue ₹183 Cr grew 94% YoY from ₹94 Cr
Supported by delivered result. Reflects post-divestment structure; comparison is complex due to Akkodis divestment timing.
Supported
Defense revenue ₹125 Cr up 112% YoY; XiDA ₹49.5 Cr up 63% YoY at 33% margin
Numbers are real, but mask quality concerns. Defense EBITDA ₹2.6 Cr reported; underlying ₹11.2 Cr after ₹9.62 Cr receivable provision. XiDA includes 46% acquisition contribution.
Supported (with caveats)
Order book visibility ₹4,500+ Cr; 8 design/order wins since April
Represents 'assured forecast visibility' over next 3 years (before FY30), not near-term revenue. Multi-year commitment, not Q1 or even Q2-Q3 conversion.
Supported (multi-year, not imminent)
What changed on this call
Guidance reframed as pro-forma. Prior call (Q3 FY26) promised 40-50% EPS growth for both FY26 and FY27, with 20% EBITDA margin target. Q1 FY27 delivered -₹14.8 crore PAT (continuing entity), sharply contradicting that trajectory. Management has not formally withdrawn the guidance, but reframed FY27 as ₹1,377 crore revenue and ₹270 crore EBITDA (~19.6% margin) on a pro-forma basis—heavily weighted toward the aerospace acquisition not yet closed, and assuming 4 M&A closures this fiscal year. This is an implicit downgrade from the prior explicit guidance. Product mix accelerated via divestment. Divested engineering services (₹163 Cr revenue, mature, low-margin) and aerospace services (~₹70-80 Cr annualized). Retaining defense (₹125 Cr at <10% EBITDA margin after provision), XiDA (₹49.5 Cr at 30% margin), and incoming aerospace manufacturing (acquisition pending). Net-net: continuing ops are now more defense and electronics-heavy, less services-dependent—strategically sound, but near-term margin severely compressed from the loss of a cash-generative services business.
The bull-bear ledger
Defense order book ₹4,557 Cr with 8 recent wins (directed energy weapons, BrahMos seeker, Kusha missiles, Uttam radar). Forecast visibility over 3 years, backed by Ministry of Defense commitment.
XiDA ramping: ₹49.5 Cr revenue at 30% EBITDA margin. Added two marquee global tech customers (semiconductor OEM, AI hyperscaler). Secular tailwind on supply-chain diversification from China.
Divestment proceeds ₹715 Cr (Phase 1 ₹190 Cr by Aug 31, Phase 2 ₹525 Cr by Nov 30) unlocks capital for CapEx and M&A without equity dilution.
Aerospace manufacturing acquisition (₹180 Cr annualized revenue, 22% EBITDA margin target) expected Q2 close. Accretive if integration executes.
Reported loss ₹14.8 Cr despite claimed restructuring success contradicts the narrative. Even normalized, PAT of ₹20.2 Cr on ₹183 Cr revenue is weak (11% margin).
FY27 guidance (₹1,377 Cr revenue, ₹270 Cr EBITDA) is pro-forma and contingent on 4 acquisitions closing within 9 months. Binary execution risk.
Receivable provision (₹9.62 Cr) on aged defense order signals payment delays with Ministry of Defense. Realization risk on current order book.
Order book is multi-year (before FY30, ~3 years). Q1 defense revenue only ₹125 Cr. To hit 75% growth guidance for FY27, defense revenue must reach ~₹219 Cr—acceleration not yet visible.
How the street is positioned
The stock fell 2.92% on day 1 post-result, then rebounded 5.08% by day 3—a modest recovery suggesting the market initially balked at the loss but found credibility in the order book narrative after cooling off. At ₹1600.1, the stock is down 27.63% from its all-time high of ₹2211, a significant repricing that reflects skepticism on the prior 40-50% EPS growth guidance. It trades below its SMA50 (₹1645) but above SMA200 (₹1563), suggesting uncertainty rather than conviction in either direction. RSI is neutral at 56.4, volume is rising—institutional interest is picking up as the stock falls, but ownership data shows no major flows: promoter stable at 58.03%, FII steady at 1.45%, DII at 1.97%. The market is cautiously watching; it has repriced for the miss but hasn't yet committed to the restructuring narrative. Akkodis Phase 1 close (Aug 31) and aerospace acquisition close will be the credibility tests.
1 · Akkodis Phase 1 close (Aug 31): ₹190 Cr post-tax cash inflow
This is the first domino. If delayed, capital deployment stalls and CapEx ramp slows. Triggers cascade of aerospace and other M&A closures.
2 · Aerospace manufacturing acquisition (Q2): ₹180 Cr annualized revenue close
If slipped to Q3 or later, FY27 revenue guidance under pressure. Watch for margin performance; 22% EBITDA margin target vs. actual integration reality.
3 · Q2 normalized PAT run-rate: credibility test
Can Q2 deliver ₹30+ crore normalized PAT without a one-time benefit? This will validate the ₹135 crore FY27 normalized PAT guidance. Sequential improvement or stagnation will reset expectations.
AXISCADES' Q1 was a transition quarter inflected by divestment. The underlying order book (defense ₹4,557 crore, aerospace acquisition incoming) is real, and the strategic pivot toward higher-margin manufacturing and electronics is sound. But the path to ₹1,377 crore FY27 revenue and ₹270 crore EBITDA requires 4 acquisitions to close and defense revenue to grow 75%—both are binary milestones, not certainties. The market has repriced fairly from the prior guidance miss. What it needs to see: (1) Akkodis Phase 1 close on schedule, (2) aerospace acquisition delivered Q2, and (3) Q2-Q3 normalized profit trending toward ₹135 crore guidance. Until then, hold steady. The number to track: normalized PAT, not adjusted. That's where credibility sits.
Restructuring inflicts ₹14.8 Cr loss; order book visibility insufficient near-term offset
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 5/10
Grade C
Prior FY26 guidance (40-50% EPS growth, 20% EBITDA margin by FY27) appears unattainable given Q1 negative PAT trajectory. Restructuring via pro-forma accounting obscures true run-rate performance. Continued credibility pending Akkodis close (Aug 31) and aerospace acquisition delivery.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Q1 delivered a reported loss of ₹14.8 Cr despite management's normalized PAT narrative of ₹20.2 Cr. While restructuring into manufacturing/defense/electronics is strategic, execution risk on ₹4 M&A pipeline and order book conversion is substantial. Order visibility (₹4,500 Cr defense + aerospace acquisition) supports long-term Power 930 target (₹960 Cr PAT by FY30), but FY27 normalized guidance (₹1,377 Cr revenue, ₹270 Cr EBITDA) is heavily contingent on acquisition closes and demand persistence.
₹183.4 Cr
Revenue · −24.8% YoY₹-14.8 Cr
Reported PAT · −170.8% YoYCompressing
Margins · vs guidance: OverstatedDid the claims hold up?
Normalized EBITDA 41 Cr at 11.8% margin, up from 20.5% YoY
OVERSTATEDReported EBITDA 27.9 Cr; continuing ops EBITDA 8.7 Cr (4.7% margin). Math inconsistency: 41/350 total ≠ 11.8%. Normalized profit construction relies heavily on one-time adjustments (₹21.81 Cr transaction cost, ₹13.1 Cr provisions).
Continuing ops revenue grew 94% YoY to 183 Cr from 94 Cr Q1 FY26
METContinuing operations revenue ₹183.4 Cr (delivered); consolidated revenue ₹346 Cr including discontinued ops. Prior year comparison affected by divestment timing. Actual Q1 FY27 continuing entity revenue only reflects post-divestment structure.
Business earned money while paying for transformation (normalized PAT ₹20.2 Cr)
MISSReported PAT loss ₹14.8 Cr. Normalized PAT requires removing ₹34.91 Cr of costs (transaction + provisions). Without these items, implied EBITDA margin would be ~23% (41 Cr / 183 Cr), inconsistent with stated 11.8%.
Defense 125 Cr revenue up 112% YoY; XiDA 49.5 Cr up 63% YoY at 33% margin
METDefense: ₹125 Cr reported, underlying EBITDA ₹13 Cr (after 9.6 Cr receivable provision). XiDA: ₹49.5 Cr revenue, ₹14.7 Cr EBITDA (includes 46% margin acquisition contribution). Both numbers are real but masks quality questions on defense margins after provisioning.
Order book visibility ₹4,500+ Cr; 8 design/order wins since April
METStated as 'assured forecast visibility' to be executed over next 3 years (before FY30). Not a Q1 revenue number; represents multi-year commitment. Earlier pipeline cited at ₹24,000 Cr but that is 'huge pipeline which converges into forecast visibility', not near-term certain.
Earnings quality
What changed since the last call
Margin guidance implicit downgrade
DowngradeFY27 normalized EBITDA margin implied ~19.6% (₹270 Cr / ₹1,377 Cr pro-forma) vs prior 20% target and historical 20.5% in Q1 FY26 continuing ops. Current continuing ops EBITDA margin 4.7% (delivered). Gap of 15pp from historical to forward guidance suggests lower quality of growth mix post-divestment.
EPS growth guidance effective withdrawal
WithdrawnPrior Q3 FY26 guidance: 40-50% EPS growth for FY26 and FY27. Q1 FY27 delivered negative PAT ₹14.8 Cr (continuing entity). FY27 guidance now ₹135 Cr normalized PAT; exact prior-year FY26 PAT not stated in call but trajectory implies 40-50% growth is unachievable at this run rate. Guidance reframed as pro-forma including not-yet-closed acquisitions.
Product mix shift accelerated via divestment
UpgradeDivested low-margin services businesses (engineering services ₹163 Cr, aerospace services ₹~70-80 Cr). Retaining defense (₹125 Cr, <10% margin after provision), XiDA (₹49.5 Cr, 30% margin), aerospace manufacturing (acquisition pending, ₹180 Cr annualized, 22% margin target). Net-net: mix shifts to higher-margin manufacturing and electronics, supporting long-term EBITDA margin recovery if executed.
The Q&A
Analysts pressed hard on aerospace divestment (Deepak Poddar), acquisitions execution risk (Praful Rai, multiple), and PAT-level guidance visibility (Kaushik Mohan). Management held firm on strategy but provided limited granularity on near-term PAT trajectory and CapEx timing. No analyst pushed back on normalized accounting or provision adequacy. Overall: management controlled narrative but dodged precision questions on full-year PAT and guidance credibility.
Aerospace divestment rationale — Deepak Poddar
AnsweredServices OEMs consolidating. Chose to sell to global leader rather than acquire peer. Divestment proceeds fund manufacturing, higher-margin sticky business. Manufacturing leverages defense/space/electronics.
Normalized PAT guidance — Kaushik Mohan
AnsweredEBITDA ₹270 Cr, PAT broadly 50% of that (₹135 Cr). Could be higher due to debt paydown from divestment proceeds reducing interest.
Acquisition execution timeline — Kaushik Mohan
PartialAerospace Q2 close (NBO issued, advanced DD). XiDA by Q1 end. Third/fourth in Q3/Q4. Multiple in pipeline but non-binding stage currently.
Defense order book execution — Praful Rai
AnsweredCovering entire forecast visibility before FY30 (~3 years). Could be spillover to fourth year. 75% defense revenue growth FY27 guidance.
Power 930 target viability — Praful Rai
AnsweredYes, firmly on track. FY24 revenue was ₹960 Cr, which is FY30 PAT target. Acquisitions, divestments, organic growth will achieve it.
Project Kusha & MBDA progress — Mahek Talati
AnsweredOrders for mobile mast, electronics, digital beamforming. LUH Maritime 150-170 Cr visibility backed by confirmed order. Competing on 4 different Kusha modules.
BrahMos seeker development — Piyush Sarawagi
AnsweredAdvanced stage on BrahMos NG seeker prototype. Developing AESA and proprietary direct RF versions. Business contribution next financial year onwards (FY28+).
Strategic partnerships & capital deployment — Mayur Parkeria
DodgedConversations ongoing with OEM partners on precision manufacturing/electronics JVs. Early stage, takes time. OEMs become customers first, then JV partners. No timeline now but will announce updates.
Space business details — Mayur Parkeria
DodgedAnnouncements coming at Bangalore Space Expo and World Space Business Week (Paris, ~1 month). Strategic partnerships with global space players.
Defense revenue deferral recovery — Balasubramanian
PartialAlready recovered most in Q1 (₹60 Cr). Q2 will complete remaining. Not related to land systems 20-unit program; is spillover from other contracts.
CapEx guidance and bridge financing — Balasubramanian
AnsweredCapEx timed to inflows (Q2, Q3, FY28, FY29). Extraordinary gain ₹200+ Cr in Q2 close, bulk in Sep/early Q3 close. Bridge financing ~₹100-150 Cr max drawdown.
Antenna beam controller value chain — Jatin Chaddha
PartialYes, full design ownership from circuit level. Complex digital part handled in-house. Further details out of scope for call; available in private meeting.
Directed energy weapons power challenge — Jatin Chaddha
AnsweredCurrently mobile solution with full power plant. Portable solution also on cards; modules being developed. Power optimization path clear. 30 kW modular version; versions vary by requirement.
Guidance
FY27: ₹1,377 Cr revenue (continuing ops, pro-forma annualized basis)
MediumAssumes aerospace manufacturing acquisition close Q2, ongoing organic defense growth 75% YoY, XiDA 100%+ growth. Pro-forma includes ₹180 Cr aerospace annualized revenue not yet consolidated. Deferred revenue recovery (₹82 Cr) will provide sequential lift Q2-Q3.
FY27: EBITDA ₹270 Cr (~19.6% margin on ₹1,377 Cr revenue, pro-forma)
LowNormalized basis assuming one-time restructuring costs behind. Highly dependent on acquisition closures and margin profile of aerospace acquisition (22% target). Current continuing ops EBITDA margin 4.7%, normalized 11.8% (math unclear). Significant gap to guided margin.
FY27-29 CapEx ~₹1,600 Cr for facilities + ₹600 Cr acquisition costs (total ₹2,200 Cr)
LowTiming contingent on M&A closures and customer requirements. DAC under construction (ongoing). MAC construction starting soon. CAM (240k sq ft, 20 acres, Devanahalli) in planning. CapEx timed to divestment proceeds inflows: Q2 (₹190 Cr), Q3 (₹525 Cr), plus bridge financing ₹100-150 Cr. Exact allocation by year not disclosed.
Risks the call surfaced
M&A execution
HighAerospace manufacturing, XiDA, and 2+ pipeline acquisitions all required to hit FY27 revenue ₹1,377 Cr guidance. Aerospace alone represents ₹180 Cr annualized revenue. Any single deal slippage reduces top-line by ₹60-180 Cr and EBITDA by ₹15-40 Cr.
Order book realization
High₹4,557 Cr forecast visibility cited as 'assured' but is multi-year (before FY30, ~3 years) with potential 4-year spillover. Q1 actual defense revenue only ₹125 Cr. To achieve 75% YoY growth guidance for FY27, defense revenue must reach ~₹219 Cr (₹125 Cr * 1.75). Pipeline pipeline visibility ₹24,000 Cr is highly speculative ('huge pipeline converges into forecast visibility').
Receivable quality
Medium₹9.62 Cr provision taken on aged defense transaction while pursuing recovery with Ministry of Defense. Suggests payment delays, disputes, or quality claims on prior contract. This signals cash realization risk on current defense order book.
Margin accretion on new businesses
MediumAerospace acquisition pro-forma assumes 22% EBITDA margin (₹39 Cr on ₹180 Cr revenue). Integration delays, customer pushback, or rework could reduce to 15-18%, cutting ₹60-120 Cr from FY27-28 EBITDA guidance. XiDA includes 46% margin acquisition contribution; if contribution customer volume drops, margin could compress toward legacy 20% base.
Divestment timing dependency
High₹715 Cr total proceeds (Phase 1 ₹190 Cr Aug, Phase 2 ₹525 Cr Nov) fund CapEx and acquisitions. Bridge financing capped at ₹100-150 Cr; if divestment slips, capital deployment slows. MAC construction starting soon depends on Phase 1 close. Delay could push FY27 revenue targets to FY28.
ADD Solutions drag
LowADD Solutions (European unit) recorded ₹4.8 Cr EBITDA loss, ₹6.7 Cr PAT loss in Q1. Exit targeted Q4 FY27 but still in portfolio for 3 quarters, dragging P&L. If exit delayed or realization lower-than-expected, adds to FY27 headwinds.
Management
Score 6/10. Clear on restructuring narrative and order book, but evasive on precise near-term PAT trajectory and normalized accounting assumptions. CFO provided detailed breakdowns on one-time costs but normalized EBITDA margin math was inconsistent. IR effectively handled Q&A but declined deep-dives on space business and antenna beam controller architecture (citing competitive sensitivity). Mixed. Prior guidance (40-50% EPS growth for FY27) appears unachievable; Q1 negative PAT sharply misses expectations. However, divestment closures on schedule (Akkodis Phase 1 Aug 31), acquisitions in advanced stages, and order book expansion (₹332 Cr added this quarter) show execution on M&A and business development. Missed profitability target in transition quarter.
1 · Aug 31 2026
Akkodis Phase 1 close; ₹190 Cr post-tax cash inflow expected
2 · Q2 FY27
Aerospace manufacturing acquisition close; ₹180 Cr annualized revenue on-boarding
3 · Nov 30 2026
Akkodis Phase 2 close; ₹525 Cr additional cash proceeds
Order visibility (₹4,500 Cr defense + aerospace acquisition) supports long-term Power 930 target (₹960 Cr PAT by FY30), but FY27 normalized guidance (₹1,377 Cr revenue, ₹270 Cr EBITDA) is heavily contingent on acquisition closes and demand persistence.